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Stem cells are undifferentiated cells capable of proliferation, self-renewal, and production of a large number of
differentiated progeny. Stem cells exist even in malignancies. They are called cancer stem cells, which may
represent the origin of these tumors and may be one of the reasons of chemoresistance. The
phosphatidylinositol-3-kinase (PI3K)/Akt pathway is important for the maintenance of pluripotency in stem cells.
Flow cytometry assay for identifying stem cells defines a side population of cells that displays low fluorescent dye
and is highly enriched for stem cells. The dye efflux is attributed to expression of ATP-binding cassette transporters
such as P-glycoprotein and breast cancer resistance protein (BCRP)/ABCG2, which also transport a variety of
anticancer drugs. The PI3K/Akt pathway can modulate functions of ABC transporters through various mechanisms.
Reportedly, inhibition of the PI3K/Akt pathway caused BCRP translocation in hematopoietic stem cells and glioma
stem-like cells. On the other hand, a PI3K inhibitor, LY294002, reversed multidrug resistance in cancer cells that
overexpress BCRP not by affecting BCRP translocation but putatively as a competitive inhibitor. Other PI3K
inhibitors, wortmannin and PI-103, did not reverse BCRP-mediated drug resistance. Since LY294002 is a derivative of
quercetin that is a naturally occurring flavonoid, its chemical structure is similar to those of a group of flavonoids
but those of wortmannin and PI-103 are quite different. It is known that many flavonoids are inhibitors of BCRP and
PI3K. LY294002 has also been reported to exert inhibitory effects on multidrug resistance-associated protein 1
(MRP1) function via dual mechanisms, competitive block of substrate transport and modulation of expression.
Furthermore, LY294002 has been found to antagonize transport activity of P-glycoprotein without influencing its
expression. Taken together, LY294002 can inhibit all BCRP, P-glycoprotein, and MRP1, which are three major ABC
transporters that are highly expressed in stem cells and cause multidrug resistance. Due to its versatile effects,
LY294002 could be a lead compound for developing more effective and tolerable reagents for cancer treatment.
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Stem cells are undifferentiated cells capable of prolifera-
tion, self-renewal, production of a large number of dif-
ferentiated progeny, and regeneration of tissues [1]. In
addition to embryonic stem (ES) cells, stem cells also
exist in various adult tissues such as skin, bone marrow,
liver, striated muscle, and brain [1]. After tissue damage,
they not only replenish the tissue they originally resided* Correspondence: ya-imai@dokkyomed.ac.jp
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in any medium, provided the original work is pbut also may contribute to repair another tissue. Cells
with stem-cell qualities have also been identified in ma-
lignancies of hematopoietic origin and in some solid
tumors [2]. The cells, called cancer stem cells or cancer
stem-like cells, share many properties of normal stem
cell, such as relative quiescence, resistance to drugs and
toxins, an active DNA-repair capacity, and a resistance
to apoptosis, thus providing for a long lifespan.
For decades, the unregulated growth of cancers was
attributed to the serial acquisition of genetic events that
resulted in the activation of oncogenes and silencing ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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recognized that another key event in tumor progression
is the alterations of genes involved in regulation of stem
cell renewal. When cancer cells of different origins were
analyzed for their proliferative potential in various
assays, only a small minority of cells were able to prolif-
erate extensively. Those cells, i.e., cancer stem cells, are
derived either from transformed normal stem cells or
more differentiated progenitor cells that have acquired
the ability of self-renewal as a result of oncogenic muta-
tion [3]. Thus, cancer stem cells may represent the ori-
gin of cancer and furthermore would play a pivotal role
in maintaining cancer cell population. In this point of
view, characterization of cancer stem cells would be sig-
nificant and important for clinical cancer treatment.
Stem cells can be purified based on the efflux of fluor-
escent dyes such as rhodamine 123 (rho123) and
Hoechst 33342 (Hoechst). A widely used flow cytometry
assay for identifying stem cells defines a side population
(SP) of cells displaying low Hoechst fluorescence and
comprising about 0.05% of total cells [4]. This SP popu-
lation is highly enriched for lineage-specific stem cells.
The dye efflux component of the SP phenotype has been
assumed to express ATP-binding cassette (ABC) trans-
porters such as P-glycoprotein (P-gp), encoded by the
multidrug resistance 1 (MDR1) gene, and breast cancer
resistance protein (BCRP)/ABCG2. BCRP expels
Hoechst but not rho123, while P-gp expels both Hoechst
and rho123. Accordingly, normal and cancer stem cells
express high levels of P-gp and BCRP. These two ABC
transporters and multidrug resistance-associated protein
1 (MRP1)/ABCC1 constitute the three principle ABC
transporters implicated in multidrug resistance. MRP1
has also been found to be expressed in SP cells [4].
Chemoresistance and cancer stem cells
Cancer cells can acquire resistance to chemotherapy by
various mechanisms. Since most cancer cells are genetic-
ally unstable at either chromosomal or nucleotide level,
cancer cells that recur after initial chemotherapy usually
acquire drug resistance by accumulating genetic changes
which lead to a selective advantage that allows them to
survive the chemotherapy and reconstitute the popula-
tion of tumor cells. Some of these genetic changes
observed in cancer cells grown in tissue culture are a
loss of cell surface receptor or transporter for a drug,
specific metabolism of a drug, or alteration by mutation
of the specific target of a drug. In such cases, resistance
to only a small number of related drugs is observed. In
addition, cancer cells often express mechanisms that
confer simultaneous resistance to many structurally and
functionally unrelated drugs. This phenomenon, called
multidrug resistance, can result from limitation of cellu-
lar drug accumulation by limiting uptake, enhancingefflux or affecting membrane lipids such as ceramid [5].
Blocking apoptosis, activation of detoxifying drugs, re-
pair of DNA damage, and alteration in the cell cycle and
checkpoints also render cancer cells resistant to the
cytotoxic drugs [6]. Alternatively, cancer stem cells are
intrinsically resistant to chemotherapy through their qui-
escence, their capacity for DNA repair, and expression of
ABC transporters such as BCRP, P-gp, and MRP1. Can-
cer stem cells survive chemotherapy and support re-
growth of the tumor. Those ABC transporters transport
both hydrophobic and hydrophilic compounds, and play
important roles in normal physiology in the transport of
drugs [2]. Therefore, modifying functions of the ABC
transporters would be one of the attractive strategies for
overcoming multidrug resistance of cancer stem cells.
The PI3K/Akt pathway in cancer stem cells
Large scale transcriptional profiling analysis revealed that
many of the transcripts enriched in human ES cells fell
within three major signaling categories belonging to the
Ras/MAPK/ERK pathway, the phosphatidylinositol-3-kinase
(PI3K)/Akt pathway, and NFκB signaling pathways
[7]. Among these, the PI3K/Akt pathway had been
shown to be important for the maintenance of pluripo-
tency in mouse ES cells [8,9]. LY294002, which is a spe-
cific PI3K inhibitor, was shown to cause prominent cell
differentiation in human ES cells [7]. PI3K enzymes are
normally regulated by growth factors and serve to
phosphorylate phospholipids at the plasma membrane.
Activated PI3K phosphorylates phosphatidylinositol
4,5-bisphosphate (PIP2) and generates phosphatidylinosi-
tol 3,4,5-triphosphate (PIP3) which acts as a second mes-
senger. Akt interacts with PIP3 and subsequently
translocates to the plasma membrane. Akt plays a critical
role in controlling the balance between survival and
apoptosis. Recent studies indicate that numerous compo-
nents of the PI3K/Akt pathway are targeted by amplifica-
tion, mutation and translocation more frequently than
any other pathway in cancer patients, with resultant acti-
vation of the pathway [10]. In addition, it has been sug-
gested that activation of the PI3K/Akt pathway is
required for the maintenance and viability of cancer stem
cells in breast cancer, prostate cancer, and brain tumor
[11-13]. Inhibition of AKT activity in cancer stem cells
also resulted in sensitization of cells to therapy and
increased survival of mice bearing human glioma xeno-
grafts in vivo [11-14]. Hence, the PI3K/Akt pathway can
be an attractive target for cancer therapy. Inhibiting the
pathway might also result in differentiation of cancer
stem cells [15].
Inhibitor of PI3K internalizes BCRP in stem cells
The PI3K/Akt pathway can modulate functions of ABC
transporters through various mechanisms. According to
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caused BCRP internalization in cells. Mogi, et al.
reported a reduced SP fraction in the bone marrow of
Akt1-null mice [16]. Enforced expression of Akt
increased the SP fraction in the wild-type mouse bone
marrow but not in the Bcrp−/− bone marrow. They also
showed that treatment of SP cells with 10 μM of
LY294002 for 90 min promoted Bcrp translocation
from the plasma membrane to the intracellular com-
partment. Similar results have been reported concern-
ing glioma tumor stem-like cells [17]. However, the
more detailed molecular mechanism of vesicular BCRP
trafficking regulated by the PI3K/Akt pathway mostly
remains to be elucidated. Alteration of subcellular
BCRP localization was also observed in porcine non-
SP cells, LLC-PK1 [18]. Treatment with 20 μM of
LY294002 for 90 min caused BCRP internalization
from the cell surface. Transfection of the dominant-
negative Akt plasmid resulted in internalization of a
part of BCRP in LLC-PK1 cells. Therefore, it was
hypothesized that cellular distribution of BCRP mightFigure 1 Establishment of MCF-7/BCRP cells and effects of PI3K inhib
BCRP cells. Protein sample (20 μg) was loaded in each lane and BCRP was
(B) Effects of LY294002 on anticancer drug resistances of MCF-7/BCRP cells
the absence or presence of various concentrations of anticancer drugs with
presented as percentages relative to those of control cells cultured in the a
symbols, MCF-7/BCRP cells. Square, without LY294002. Lozenge, 1 μM of LY
BCRP cells. Cells (3 x 104/well) were seeded into 12-well plates, and culture
for 4 days. Cell numbers were determined, and presented as percentages r
MCF-7 cells. Dotted bars, the MCF-7/BCRP cells. (D) Effects of wortmannin o
performed in the same way as in the legend of (B). Open symbols, MCF-7
or PI-103. Lozenge, 1 μM of wortmannin or 50 nM of PI-103. Circle, 2 μM o
from Spandidos Publications. Inc. Imai Y, et al. (19).be regulated by the PI3K/Akt signaling pathway in
non-stem cells as well as stem cells.
LY294002 inhibits BCRP without affecting its translocation
However, effects of inhibition of the PI3K/Akt pathway
in cancer cell lines were different from those in stem
cells [19]. In the study, the breast cancer MCF-7 cells
were transfected with exogenous BCRP cDNA and
MCF-7/BCRP cells that stably overexpress BCRP were
established. This cell line expresses epidermal growth
factor receptor and may be under the control of its
downstream pathways such as the Ras/MAPK/ERK
pathway and the PI3K/Akt pathway. MCF-7/BCRP cells
were found to overexpress BCRP (Figure 1A) and they
showed significantly higher resistances to SN-38 and
topotecan, which are both BCRP substrate drugs, than
the corresponding parental cells (Figure 1B). MCF-7/
BCRP cells also acquired slightly more resistance to the
PI3K inhibitors (Figure 1C and data not shown), but the
degrees of resistance did not seem to be significant con-
sidering the degrees of resistance against anticanceritors on anticancer drug resistance. (A) BCRP expression in MCF-7/
detected by western blot analysis with the anti-BCRP antibody, BXP-21.
. Cells (3 x 104/well) were seeded into 12-well plates, and cultured in
or without LY294002 for 4 days. Cell numbers were determined, and
bsence of anticancer agents. Open symbols, MCF-7 cells. Closed
294002. Circle, 2 μM of LY294002. (C) LY294002 resistance of MCF-7/
d in the absence or presence of various concentrations of LY294002
elative to those of control cells cultured without LY294002. Open bars,
r PI-103 on SN-38 resistances of MCF-7/BCRP cells. Experiment was
cells. Closed symbols, MCF-7/BCRP cells. Square, without wortmannin
f wortmannin or 100 nM of PI-103. Partially reproduced by permission
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SN-38 and topotecan on MCF-7/BCRP cells in a dose-
dependent manner, while it little affected the cytotoxici-
ties on MCF-7 cells (Figure 1B). On the other hand,
wortmannin and PI-103 did not show any significant re-
versing effects of BCRP-mediated drug resistances in the
cells (Figure 1D and data not shown). LY294002 treat-
ment reversed BCRP-mediated multidrug resistance, but
total BCRP levels (Figure 2A) or cell surface BCRP levels
(Figure 2B) in MCF-7/BCRP cells were not affected by
the treatment with up to 5 or 2 μM of LY294002, re-
spectively. Effects of LY294002 on cellular accumulation
of topotecan were then evaluated by flow cytometric
analysis. Cellular topotecan uptake was remarkable in
the parental MCF-7 cells but not in the MCF-7/BCRP
cells in the absence of LY294002 (Figure 2C). LY294002
treatment at the concentrations of 10–20 μM clearlyFigure 2 Effects of LY294002 on BCRP expression and function. (A) Ef
the absence or presence of various concentrations of LY294002 for 24 h. A
lane and western blot analysis was performed. (B) FACS analysis of BCRP ex
without 2 μM of LY294002, respectively. Trypsinized cells (5 x 105–106) wer
5D3, washed and incubated with R-phycoerythrin-conjugated streptavidin.
lines indicate control fluorescence in the presence of mouse IgG. (C) Effect
Trypsinized cells (5 x 105) were pre-incubated with indicated concentration
line) or without (dotted line) 40 μM of topotecan for 30 min in the absenc
measured by flow cytometry. Reproduced by permission from Spandidos Pdemonstrated increased cellular topotecan uptake in a
dose-dependent manner in the medium containing 40
μM of topotecan (Figure 2C). The effects were weaker
than those of gefitinib but were stronger than estrone in
this situation (data not shown). This surprising result
suggested that trafficking problem was not a main rea-
son for the loss of BCRP function mediated by
LY294002. Fluorescence immunohistochemistry con-
firmed that MCF-7/BCRP cells treated with LY294002
expressed BCRP mainly on the plasma membrane in this
experimental setting (Figure 3).
For the past decade, PI3K/Akt inhibitors have been
known to cause more favorable outcomes when co-
administered with usual anticancer drugs. Deregulation
of drug transporters is one of the postulated mechan-
isms. It had been reported that inhibition of the PI3K/
Akt pathway modulated BCRP-mediated drug transportfects of LY294002 on BCRP protein expression. Cells were cultured in
fter harvesting the cells, protein sample (20 μg) was loaded in each
pression on the cell surface. Cells were incubated for 12 h with or
e incubated with either biotinylated mouse IgG or anti-human ABCG2,
Bold lines indicate fluorescence in the presence of 5D3 and dotted
s of LY294002 on cellular topotecan uptake of MCF-7/BCRP cells.
s of reagents for 60 min. The cells were then incubated with (solid
e or presence of the reagents. Finally, cellular topotecan uptake was
ublications. Inc. Imai Y, et al. (19).
Figure 3 Immunofluorescence analysis of the subcellular BCRP localization. Cells were treated with 2 μM of LY294002 for 12 h, collected as
a cell block, formalin-fixed, paraffin-embedded, and processed. BCRP was detected as green fluorescence, while cell nuclei were indicated by
purple fluorescence. Scale bar, 30 μm. Reproduced by permission from Spandidos Publications. Inc. Imai Y, et al. (19).
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and glioma stem-like cells. It was also reported that
inhibition of the PI3K/Akt pathway resulted in BCRP
translocation in renal polarized cells [16-18]. However,
effects of the PI3K/Akt inhibitors on BCRP function
were found to be considerably different in BCRP-
transfected MCF-7 cells. LY294002 did not affect cel-
lular BCRP distribution in the cancer cell line but
exerted inhibitory effects on BCRP-mediated topotecan
efflux. Thus, LY294002 demonstrated BCRP-inhibitory
effects different from those observed in the previous
studies. Then, two possible explanations were postu-
lated to explain the results. The first one was the dif-
ference of cell characters between stem cells and
non-stem cells. Regulation of subcellular BCRP distri-
bution by the PI3K/Akt pathway might be specific to
a subset of cells such as stem/stem-like cells. It is
known that the PI3K/Akt signaling pathway is acti-
vated and plays a role in the maintenance of pluripo-
tency and viability of stem cells [7]. BCRP is
expressed on the cell surface of pluripotent stem cells
but becomes downregulated with cell maturation. On
the other hand, the PI3K/Akt signals have been
reported to regulate activity and trafficking of some
transporters and/or receptors, such as transferrin re-
ceptor, low-density lipoprotein receptor, the amino-
acid transporter 4F2, integrin, and Glut1 through
regulating endocytosis and recycling [20,21]. There-
fore, the PI3K/Akt signaling pathway might be
involved in mechanisms of BCRP trafficking to the
cell surface and maintenance of the pluripotency of
stem cells. Another explanation was that some of the
BCRP protein might be internalized, but expression
levels of overexpessed BCRP in cancer cells are too
high to discern internalized BCRP and most of BCRP
would be left uninternalized. But, it was supposed thatthis hypothesis could not successfully explain the data
that LY294002 clearly and remarkably sensitized MCF-
7/BCRP cells to BCRP-substrate drugs. Accordingly,
interaction of LY294002 with the drug binding sites
of BCRP was thought to explain the reversal effects.
Since BCRP overexpression did not result in acquisi-
tion of comparable degrees of LY294002 resistance
with those of anticancer drugs (Figure 1C), LY294002
would not be a transport substrate of BCRP but it
would competitively interact with the drug binding
site.
Inhibitory effects of LY294002 on MRP1 and P-gp
LY294002 has been reported to competitively inhibit
MRP1-mediated doxorubicin transport [22]. Besides,
MRP1 expression has been found to be regulated by the
PI3K/Akt pathway. Treatment of myelogenous leukemia
cells with wortmannin resulted in lower levels of phos-
phorylated Akt, downregulated MRP1 expression, and
decreased rho123 extrusion in dye efflux assay [23]. In
another report, modulation of PI3K activity with the use
of constitutively active and dominant-negative inhibitors
was found to affect the ability of prostate cancer cells to
respond to chemotoxic treatments [24]. MRP1 expres-
sion was upregulated as a consequence of PI3K activa-
tion in prostate cancer cells. Thus, LY294002 can also
exert inhibitory effects on MRP1 function via dual
mechanisms, i.e., competitive block of substrate trans-
port and modulation of expression.
LY294002 has also been observed to antagonize trans-
port activity of P-gp without influencing its expression
and antagonize P-gp-mediated multidrug resistance [25].
Authors of this report discussed that suppression of the
apoptotic pathway and regulation mechanism of the
transport activity controlled by the PI3K/Akt kinase
pathway might be additive to P-gp-mediated drug
Figure 4 Chemical structures of the PI3K inhibitors and related
flavonoids.
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pathway were not tested in the report, and we suspect
that inhibition of P-gp-mediated drug transport by
LY294002 might have been irrelevant to inhibition of theFigure 5 Summary of inhibitory effects of LY294002 on the PI3K/Akt sigPI3K/Akt pathway. Taken together, LY294002 can inhibit
all P-gp, MRP1 and BCRP.
Flavonoid as seeds of cancer chemotherapeutic drugs
LY294002 was designed as a synthetic PI3K inhibitor
based on quercetin, a naturally occurring flavonoid.
Quercetin and other flavonoids had been found to re-
verse BCRP-mediated drug resistance to variable degrees
in the previous study [26]. In fact, the chemical structure
of LY294002 is very similar to those of quercetin and the
strongest flavonoid that reverses BCRP-mediated drug
resistance, acacetin. But the chemical structures of wort-
mannin and PI-103 are quite different (Figure 4). Flavo-
noids are polyphenolic compounds which are abundant
in fruits, vegetables, and plant-derived beverages such as
tea, green tea and wine. Flavonoids inhibit a broad range
of protein kinases including PI3K [27-29]. It was
reported that inhibitory activity against PI3K was noted
in many flavonoids, among which flavonols (kaempferol,
quercetin, myricetin, quercetagetin, et al.) showed very
strong inhibitory effects [29]. These naturally occurring
substances can inhibit PI3K kinase activity and function
of ABC transporters by altering cellular distribution and
by competitive block of substrate transport. Therefore,
flavonoids and their derivatives could be a promising
source of anticancer drugs.
Conclusions
In addition to BCRP-internalizing effect in stem cells,
LY294002 would competitively inhibit transport activity
of BCRP. LY294002 also inhibits transport by P-gp and
MRP1. Since LY294002 thus exerts versatile inhibitory
effects on the ABC transporters that characterize stem
cells and cancer stem cells (Figure 5), it can be a lead fornaling pathway and ABC transporters that characterize stem cells.
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cer treatment. On the other hand, LY294002 and its
derivatives may cause severe adverse effects by inhibiting
many cellular signaling pathways and transporters and/
or channels simultaneously. Potential side effects should
be fully investigated using in-vivo models before clinical
use. Furthermore, the most intriguing question that
remains unresolved is why inhibiting the PI3K/Akt path-
way results in internalization of BCRP in stem cells but
not in non-stem cells. Elucidating this point would
greatly add much on the strategy of cancer chemother-
apy in the future.
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